EGF and neoplasm: miR-200c has been reported to reduce sensitivity of CD95-mediated apoptosis in tumor cells by targeting Fas-associated phosphatase-1 (FAP-1) [44], suppress migration and anoikis resistance by targeting moesin (MSN), fibronectin 1 (FN1) and neurotrophic tyrosine receptor kinase type 2 (TrkB) [45] and negatively regulate EGF-driven cell proliferation and motility by targeting phospholipase C gamma 1 (PLCG1) [46].